Professor Martin Sullivan Foot and Ankle Surgeon at St. Vincent’s Clinic & North Shore Private Hospital in Sydney presents ‘An Australian Perspective on the Management of Large Cartilage Defects in the Ankle Over 25 Years’
Video | Proactive Investors Interview – September 2020
Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about the company being in an exciting regulatory phase, having validated its technologies in the clinic and defining pathways to market through the US FDA process.
Australia’s Orthocell submits 510(k) for Celgro™ regenerative collagen medical device
Orthocell has been featured in BioWorld, following the submission of a 510(k) application to the U.S. FDA for our Celgroâ„¢ collagen medical device for dental guided bone and soft tissue regeneration applications.
Orthocell looks to enter US market following positive CelGroâ„¢ study results
Small Caps has featured Orthocell’s plans to enter the US market following the success of our Celgroâ„¢ dental implant study.Â
Orthocell – The Next Big Winner In The Regenerative Sector
Greg Tolpigin has published positive commentary about the future of Orthocell, and the potential for our CelGroâ„¢ product in this article on Sharecafe.Â
Orthocell receives patent for breakthrough CelGro ‘collagen rope’ to treat ACL injuries
Small Caps has reported on Orthocell’s recent patent announcement for our breakthrough CelGro collagen rope device to enhance the surgical repair of anterior cruciate ligament (ACL) injuries.
Australia’s Orthocell ready to file on interim Celgro™ data
BioWorld has reported on Orthocell’s plans to seek early FDA approval for our Celgroâ„¢ nerve regeneration treatment, following positive interim clinical results in quadriplegic patients.
Orthocell on course to revolutionise nerve regeneration after positive interim clinical results
Orthocell has been featured in Small Caps following positive interim clinical results for CelGroâ„¢, a collagen medical device that facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications.
Orthocell shares boosted by nerve repair trial success
Journalist Sarah Jane Tasker, from The Australian, discusses the positive results from Orthocell’s clinical trial of nerve repair product, CelGroâ„¢, in quadriplegic patients.
Orthocell reports high success rate from CelGro surgical trial on patients with rotator cuff injuries
Small Caps has reported on the follow-up results from our CelGroâ„¢ tendon regeneration clinical trial, confirming all patients with rotator cuff injuries achieved a successful tendon repair with no need for revision surgeries.